Equity Research Biotechnology

Should You Buy SciSparc Ltd. Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, SciSparc Ltd. (SPRC) registers a weak Quality of Company score of 1.7/10. At the current price of $4.76, our 13-model framework evaluates whether the stock's discount is sufficient to compensate for high fundamental risks.

The short answer: 0 of 1 CirclFi valuation models project upside for SciSparc Ltd. (SPRC) at $4.76 — the model consensus leans bearish, with a Quality Score of 1.7/10 and Value-Trap risk of 80/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 1.7/10 — Very Weak — significant concerns
  • Value Trap Risk: 80/100 — High danger — likely trap
  • Fair Value Range: $1.85 – $1.85 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

1.7 /10

Very Weak — significant concerns

Value Trap Risk

80 /100
High danger

High danger — likely trap

Model Consensus

1 /13
Active Models

Avg. confidence: 28%

What Is the Investment Case for SciSparc Ltd. (SPRC) in 2026?

What Is the Bull Case vs the Bear Case for SciSparc Ltd. (SPRC)?

Bull case versus bear case for SciSparc Ltd. (SPRC) at $4.76, derived from 1 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $1.85 target (-61.2%)
No active model projects meaningful upside for SPRC at $4.76. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Quality of Company (QOC) framework, SciSparc Ltd.'s score of 1.7/10 signals fundamental weaknesses that could undermine the investment thesis.
According to the CirclFi Value Trap detector, SciSparc Ltd. is flagged with elevated risk (Value Trap score of 80/100), suggesting that apparent cheapness may mask fundamental decay.
According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $1.85 (-61.2%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: reimbursement uncertainty represents a meaningful risk for SciSparc Ltd. and its Biotechnology peers.

How Does SPRC Compare to Its Biotechnology Peers?

MDWD MediWound Ltd.
1.9
EXEL Exelixis, Inc.
9.6
PLRZ Polyrizon Ltd.
2.0
INCY Incyte Corporation
9.5
PBM Psyence Biomedical L
2.0
ALNY Alnylam Pharmaceutic
9.5
RYTM Rhythm Pharmaceutica
5.9
CABA Cabaletta Bio, Inc.
5.0

Valuation data pages: MDWD · EXEL · PLRZ · INCY · PBM · ALNY · RYTM · CABA · PTHS

See full Biotechnology rankings →

Which Other Stocks Score Like SPRC on Quality?

Closest companies to SPRC’s Quality of Company score of 1.7/10, across all industries.

  • ZNB — Zeta Network Group (QOC 1.8) · analysis
  • GDHG — Golden Heaven Group Holdings Ltd. (QOC 1.7) · analysis
  • RDGT — Ridgetech, Inc. (QOC 1.8) · analysis
  • ILAG — Intelligent Living Application Group Inc. (QOC 1.7) · analysis
  • AGMH — AGM Group Holdings Inc. (QOC 1.8) · analysis
  • SMX — SMX (Security Matters) Public Limited Company (QOC 1.7) · analysis
  • NVDA — NVIDIA Corporation (QOC 10.0) · analysis

Why Do CirclFi’s 1 Models Disagree on SPRC?

Spread

0%

Fair Value Range

$1.85 – $1.85

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Regime Cross

$1.85 (-61.2%)

Most Bearish

Regime Cross

$1.85 (-61.2%)

What Are the Biggest Risks of Buying SPRC Stock?

Weak Fundamentals

QOC 1.7/10 signals below-average quality.

Value Trap Warning

VT score 80/100 — apparent discount may mask decay.

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View SPRC Data Page →

So Is SciSparc Ltd. (SPRC) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on SciSparc Ltd. at $4.76. 1/1 models flag overvaluation, median fair value sits at $1.85 (-61.2%), and value trap risk is elevated. Quality at 1.7/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. SciSparc Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About SPRC Stock?

Should I buy SPRC stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for SPRC at $4.76. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in SciSparc Ltd.?

Key risks include: an elevated Value Trap score of 80/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 1.7/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does SPRC compare to its competitors?

Among Biotechnology peers, SPRC holds a Quality Score of 1.7/10. Comparable companies include MDWD (QOC 1.9), EXEL (QOC 9.6), PLRZ (QOC 2.0). The relative ranking helps investors identify whether SPRC offers better fundamental quality than alternatives in the same sector.

Is SPRC a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SPRC's Quality Score of 1.7/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy SPRC at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $1.85 to $1.85. At $4.76, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for SPRC.

View SPRC Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →